Vast Therapeutics is a development stage pharmaceutical company focused on creating therapies to combat resistant bacteria and enhance respiratory health. The company operates in the biotechnology and pharmaceutical markets, targeting patients suffering from severe respiratory diseases. Vast Therapeutics primarily serves healthcare providers and patients who require advanced treatments for conditions like Nontuberculous Mycobacteria (NTM) infections.

The business model revolves around the research and development of innovative drug candidates, such as BIOC11, which has shown promising results in eradicating 99% of NTM in animal models. The company generates revenue through equity financing and aims to commercialize its therapies upon successful clinical trials and regulatory approvals.

Vast Therapeutics is a subsidiary of KNOW Bio, LLC, and benefits from the conglomerate's resources and expertise in biotechnology and MedTech. The company recently secured $30 million in equity financing from Reedy Creek Investments, LLC, which will support its ongoing research and development efforts.

Keywords: resistant bacteria, respiratory health, biotechnology, pharmaceutical, NTM infections, BIOC11, drug development, clinical trials, equity financing, KNOW Bio.